Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome
Por:
Carmona-Iragui, M, Santos, T, Videla, S, Fernandez, S, Benejam, B, Videla, L, Alcolea, D, Blennow, K, Blesa, R, Lleo, A, Fortea, J
Publicada:
1 ene 2017
Resumen:
Background: Alzheimer's disease (AD) is the main medical problem in older adults with Down syndrome (DS). Studies of cerebrospinal fluid (CSF) AD biomarkers are limited and the feasibility of lumbar puncture (LP) is controversial in this population.
Objective: To analyze the frequency of complications after a LP in DS.
Methods: We collected data from 80 adults with DS that underwent a LP within the Down Alzheimer Barcelona Neuroimaging Initiative. Demographics, cognitive status, headache history, and presence of complications after the LP were recorded in every subject. In 53 of them (active group), this information was collected following a semi-structured and validated protocol that actively looks for complications. Other variables related to the LP procedure were also recorded. A telephone interview to the caregiver was performed 5-7 days after the procedure to ask about complications. Data from 27 subjects (clinical practice group), from whom the presence of complications was obtained in a medical follow-up visit within the three months after the LP, were also included.
Results: There were no adverse events in 90% of our participants. The most frequent complication was headache (6.25%); only one subject reported a typical post-lumbar puncture headache with moderate severity that required analgesic treatment. Dizziness (3.75%) and back pain (1.25%) were also reported. All the participants that reported complications belonged to the active group.
Conclusion: LP can be safely performed to study CSF biomarkers in DS. The reported complications are qualitatively similar to the general population, but are less frequently reported, even when actively searched for.
Filiaciones:
Carmona-Iragui, M:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Biomed Res Inst St Pau, Memory Unit,Dept Neurol, Barcelona, Spain
Fundacio Catalana Sindrome Down, Barcelona Med Ctr, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
Santos, T:
Ctr Hosp Vila Nova de Gaia Espinho, Dept Neurol, Oporto, Portugal
Videla, S:
Fundacio Catalana Sindrome Down, Barcelona Med Ctr, Barcelona, Spain
Univ Pompeu Fabra, Dept Expt & Hlth Sci, Fac Hlth & Life Sci, Barcelona, Spain
Fernandez, S:
Fundacio Catalana Sindrome Down, Barcelona Med Ctr, Barcelona, Spain
Benejam, B:
Fundacio Catalana Sindrome Down, Barcelona Med Ctr, Barcelona, Spain
Videla, L:
Fundacio Catalana Sindrome Down, Barcelona Med Ctr, Barcelona, Spain
Alcolea, D:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Biomed Res Inst St Pau, Memory Unit,Dept Neurol, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
Blennow, K:
Univ Gothenburg, Clin Neurochem Lab, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden
Blesa, R:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Biomed Res Inst St Pau, Memory Unit,Dept Neurol, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
Lleo, A:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Biomed Res Inst St Pau, Memory Unit,Dept Neurol, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
Fortea, J:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Biomed Res Inst St Pau, Memory Unit,Dept Neurol, Barcelona, Spain
Fundacio Catalana Sindrome Down, Barcelona Med Ctr, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
Green Published
|